Is Sanofi (ENXTPA:SAN) Cheap Following MenQuadfi Approval For Infants?
EC approval for MenQuadfi expansion puts Sanofi stock in focus
The European Commission has approved an expanded indication for MenQuadfi, allowing Sanofi (ENXTPA:SAN) to offer its meningococcal vaccine to infants from six weeks of age, extending coverage beyond the previous 12 months and older group.
This change targets one of the highest risk populations for invasive meningococcal disease and is supported by comprehensive clinical data on immunogenicity and safety. For investors, it raises questions about how Sanofi’s vaccine portfolio, overall earnings profile and recent share price performance fit together.
See our latest analysis for Sanofi.
Sanofi’s EC approval for MenQuadfi comes shortly after half year 2026 results that showed €22,106 million in sales and higher impairment charges. A completed €1,009 million share buyback and ongoing vaccine trials frame a mixed backdrop where short term share price momentum appears muted and longer term total shareholder returns have also been subdued.
If you are comparing Sanofi’s vaccine story with other health related growth ideas, it can be helpful to scan 129 healthcare AI stocks for potential additions to your watchlist.
Sanofi shares have drifted over the past year despite new vaccine milestones and a completed €1,009 million buyback. The current valuation now raises a sharper question: Is most of the upside still ahead or already behind the stock?
Most Popular Narrative: 22.1% Undervalued
Sanofi’s most followed valuation narrative puts fair value at €96.70, well above the last close of €75.31, which frames MenQuadfi’s wider use within a bigger earnings story.
Sanofi's ongoing focus on innovative product launches and its strong R&D pipeline, highlighted by accelerating investments, multiple Phase III readouts through 2026, and continued expansion of biologics (e.g., Dupixent, amlitelimab), position the company to capture higher demand for chronic disease treatments in a world with an aging population, supporting robust long-term sales growth and EPS upside. (Revenue, EPS)
Want to see what sits behind that ambitious fair value for Sanofi. The narrative leans heavily on revenue expansion, margin shifts and a lower future earnings multiple. The mix of pipelines, product launches and capital allocation assumptions does a lot of heavy lifting here. The detail shows exactly how those moving parts are expected to add up.
Result: Fair Value of €96.70 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Sanofi story also faces pressure from pricing competition in vaccines and uncertainty around pipeline execution, which could challenge the more optimistic valuation narrative.
Find out about the key risks to this Sanofi narrative.
Next Steps
With both risks and rewards in play for Sanofi, it makes sense to move quickly and review the underlying data yourself. A helpful place to start is by weighing the 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Sanofi?
If you only focus on Sanofi, you might miss other opportunities that suit your goals. Take a few minutes to scan fresh ideas built from solid data.
- Spot potential upside early by checking companies our tools flag as promising value opportunities through the 255 high quality undervalued stocks.
- Strengthen your income focus by reviewing companies screened as potential 439 dividend fortresses.
- Sleep easier at night by shortlisting companies identified in our 299 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com